期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼治疗晚期非小细胞肺癌不良反应的观察及护理 被引量：19

Adverse reaction monitoring and nursing care of patients taking Iressa to treat late non- small-cell lung cancer
原文传递
导出
摘要 目的对晚期非小细胞肺癌病人应用吉非替尼后的疗效及不良反应进行观察。方法选择182例晚期非小细胞肺癌病人,应用吉非替尼治疗90d后对其疗效及不良反应进行观察。结果本组发生皮疹87例(47.8%),腹泻51例(28.0%),恶心、呕吐26例(14.3%),转氨酶升高21例(11.5%),间质性肺炎1例(0.5%)。结论晚期非小细胞肺癌病人应用吉非替尼治疗出现不良反应时,及时进行护理干预和对症处理至关重要,能有效地提高病人的生存质量。
作者 周小平 缪景霞 廖荣荣 钱敏
机构地区 南方医科大学南方医院肿瘤科
出处 《中华护理杂志》 CSCD 北大核心 2005年第11期834-835,共2页 Chinese Journal of Nursing
关键词 吉非替尼 癌 非小细胞肺 护理 Gefitinib Carcinoma,non-small-cell lung Nursing care
分类号 R473.73 [医药卫生—护理学]
  • 相关文献

参考文献5

  • 1Sirotnak FM. Studies with ZD1839 in preelinical models. Semin Oneol,2003,30 ( 1 Suppl 1) : 12-20.
  • 2Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol, 2003,30(1 Suppl 1):3 11.
  • 3谢剑明,曹梦苒,罗荣城.ZD1839治疗43例晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2004,9(6):581-585. 被引量：8
  • 4Schiller JH. New directions for ZD1839 in the treatment of solid tumors.Semin Oncol, 2003,30(1 Suppl 1) :49-55.
  • 5Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer,2003,40(3):339-342.

二级参考文献9

  • 1Fukuoka M,Yano S,Giaccone G, et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003 Jun 15,21(12):2237-2246.Epub 2003 May 14.
  • 2LoRusso PM,Herbst RS,Rischin D, et al.Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors[J].Clin Cancer Res,2003 Jun,9(6):2040-2048.
  • 3Schiller JH.New directions for ZD1839 in the treatment of solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):49-55.
  • 4Baselga J,Rischin D,Ranson M.Calvert HPhase I safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002 Nov 1,20(21):4292-4302.
  • 5Lorusso PM.Phase I studies of ZD1839 in patients with eommon solid tumors[J].Semin Oncol,2003 Feb,30(1 Suppl 1):21-29.
  • 6Okamoto I,Fujii K,Matsumoto M, et al.Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer[J].Lung Cancer,2003 Jun,40(3):339-342.
  • 7Sirotnak FM.Studies with ZD1839 in preclinical models[J].Semin Oncol,2003 Feb,30(1 Suppl 1):12-20.
  • 8Ritter CA,Arteaga CL.The epidermal growth factor receptor-tyrosine kinase:a promising therapeutic target in solid tumors[J].Semin Oncol,2003 Fed,30(1 Suppl 1):3-11.
  • 9Herbst RS.Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J].Semin Oncol,2003 Feb,30(1 Suppl 1):30-38.

共引文献7

同被引文献195

引证文献19

二级引证文献72

中华护理杂志
2005年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部